Results

1–10 of 49 results for suprachoroidal

Durability and Safety of Suprachoroidal Triamcinolone Acetonide in Eyes with Chronic Cystoid Macular Edema in Real-world Clinical Practice
Sunir J. Garg, MD, FACS, FASRS
Updates from the Field
2026
Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy The Phase II ALTITUDE Study
Dilsher S. Dhoot, MD
Annual Meeting Talks
2023
Kissing Choroidals
Talhah - Zubair, MD
Hossein Nazari, MD, PhD
Retina Image Bank: Images of the Week
2025
Phase 2 Trial of Belzupacap Sarotalocan (Bel-Sar, AU-011), a Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration
Amy C. Schefler, MD FACS FASRS
Annual Meeting Talks
2023
Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2023
Suprachoroidal Delivery of RGX-314 for Neovascular AMD Results of the Phase II AAVIATE Study
David S. Boyer, MD
Annual Meeting Talks
2023
Intraocular Pressure Elevation Immediately Following High-Volume (0.07 mL-0.15 mL) vs Standard Volume (0.05 mL) Injections
Scott D Walter, MD, MSc, FASRS
Annual Meeting Talks
2024
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Danny A. Mammo, MD
Annual Meeting Talks
2024
A Randomized Trial Comparing Suprachoroidal Injection of Triamcinolone and Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema
Murat Oncel, MD, FASRS
Annual Meeting Talks
2024
Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Diabetic Retinopathy: The Phase II ALTITUDE® Study
Margaret A. Chang, MD, MS
Updates from the Field
2025